The Tendinopathy market is expected to boom with the launch of the potential Tendinopathy pipeline drugs such as Micronized DHACM and Amniotic Fluid Tissue in the forecasted period (2021-2030).
LAS VEGAS, July 28, 2021 /PRNewswire/ -- DelveInsight's "Tendinopathy Market" report provides a thorough comprehension of the Tendinopathy historical and forecasted epidemiology and the Tendinopathy market trends in the 7MM [the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan]. The Tendinopathy market report also proffers an analysis of the current Tendinopathy treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Several key pharmaceutical companies like MiMedx Group, R3 Stem Cell, Novartis Pharmaceuticals, University of Wisconsin-Madison, General Electric, Ipsen, Orthocell Limited, and others are developing novel products to improve the Tendinopathy treatment outlook.
Tendinopathy Market growth will expand due to the factors such as the rising incidence, research and development, preclinical models, and the approval of pipeline drugs in the forecasted period. Nevertheless, the growth of the Tendinopathy Market will impede because of delayed diagnosis, misdiagnosis, and the limitations associated with the current treatment.
The current market depends on therapeutic agents or those who fail to respond to these drugs and go for surgery. However, by looking at the pipeline, it has been found that many allografts, regenerative medicine treatments with amniotic fluid, and cell therapy are under development for Tendinopathy. Moreover, if they get approved in the coming years, they will capture all the market of NSAIDs, opioids, and other therapies that are providing symptomatic management.
Tendinopathy is a failed healing response of the tendon, with the haphazard proliferation of tenocytes, intracellular abnormalities in tenocytes, disruption of collagen fibers, and a subsequent increase in the noncollagenous matrix.
DelveInsight estimates that the total Tendinopathy incident cases were found to be 29,282,773 cases in the 7MM in 2020. Among these countries, the United States patients account for the highest number of Tendinopathy cases.
The traditional Tendinopathy treatment modalities aimed at controlling inflammation, such as corticosteroid injections and nonsteroidal anti-inflammatory medications (NSAIDs), may not be the most effective options. Platelet-Rich Plasma (PRP) is another technique that has been widely used in orthopedic surgery and sports medicine to treat tendon injuries.
The current Tendinopathy treatment regimen for the management includes rest, ice, and over-the-counter (OTC) pain relievers. Certain medications, including over-the-counter non-steroidal anti-inflammatory medications, such as ibuprofen and naproxen, are recommended for managing the condition.
Out of the current treatment market, most of the Tendinopathy market size was generated by Surgery + NSAIDs, which is around USD 6,252 million in the 7MM in 2020. However, with the expected approval of the emergence of emerging products, the market size of Surgery + NSAIDs is expected to decrease in 2030.
The Tendinopathy pipeline possesses potential drugs as monotherapies as well as combination therapies. The current market of Tendinopathy anticipates the emergence of emerging products, namely Micronized DHACM and Amniotic Fluid Tissue. Most of the drugs are approved for tendonitis; hence, there is a need to approve more tendinopathy-specific drugs, and robust pipeline candidates are expected to intensify future competition.
The growth of the Tendinopathy Market will increase owing to the Tendinopathy incidence in recent years and the overall rise in extreme and overuse sports. Significant advancements in the field of Tendinopathy therapeutics are observed. In addition, various organizations and research institutes are undertaking research activities to discover successful Tendinopathy treatments, and a large number of clinical trials are recruiting Tendinopathy patient volunteers. Moreover, gene therapy becomes a promising method for facilitating the trafficking of growth factors to the injured site, potentially allowing sustained temporal delivery. Novel mini-invasive procedures that target underlying pathology, such as abnormal neoinnervation, are being developed and are initially promising.
Nevertheless, the lack of understanding of the disease pathophysiology and clinical relevance may represent a missed opportunity to make the correct diagnosis, potentially leading to a delayed diagnosis and misdiagnosis. Despite many clinical advances in treating Tendinopathies, there remains an unmet need for effective therapeutic strategies to augment the intrinsic and surgical repair. Already available off-labeled drugs might offer tough competition to emerging ones. Also, the communication gap among doctors and patients is one of the primary reasons for unsatisfactory patient care currently and might hinder the growth of the Tendinopathy market and access to medications.
Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
Tendinopathy Markets Segmentation: By Geographies and By Tendinopathy Therapies (Historical and Forecasted, Current and Upcoming)
Dominant Market Companies investigating its candidates for Tendinopathy: MiMedx Group, R3 Stem Cell, Novartis Pharmaceuticals, University of Wisconsin-Madison, General Electric, Ipsen, Orthocell Limited, and several others.
Analysis: Comparative and conjoint analysis of emerging therapies.
DelveInsight's Anemia in CKD patients - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and Epidemiology Forecast in 7MM.
DelveInsight's 'Balloon Catheters Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Balloon Catheters, historical, forecasted epidemiology, and market trends in the 7MM. Key Players such as Cardionovum GmbH, Boston Scientific Corporation, Biotronik, Abbott, Terumo Medical Corporation, Medtronic, and others are developing devices.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also providesBusiness Consulting Serviceswith a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.